MAY 1 9 2006



Aegera Therapeutics Inc. 810 Chemin du Golf, Montreal, Quebec H3E 1A8 Canada Tel: 514.288.4091 Ext:353 Fax: 514.288.9280

Facsimile Transmittal Sheet / Télécopie

To/A:	United States Patent and Trademark Office		Application No: 10/636,065
Fr/De:	Aegera Therapeutics Inc		·
Fax:	571-273-8300	Pages:	3 Including Cover
ATT:		Date:	May 19 2006
Re:	Revocation of Power of Attorne Correspondence Address. Statement Under 37C.F.R.§ 3.75		ew Power of Attorney and Change of

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply email. No warranty is made that the e-mail or attachment(s) are free from computer virus or other defect.

RECEIVED CENTRAL FAX CENTER

MAY 1 9 2006

PTO/SBR2 (01-06)
Approved for use through 12/31/2006, OMB 0651-0035
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF **ATTORNEY WITH NEW POWER OF ATTORNEY** AND

CHANGE OF CORRESPONDENCE ADDRESS

Application Number	10/636,065
Filing Date	August 7, 2003
First Named Inventor	Robert G. Korneluk
Art Unit	1835
Examiner Name	Jone J. Zere
Attorney Docket Number	

I hereby revoke all previous powers of attorney given in the above-identified application.								
A Power of Attorney is submitted herewith.								
OR I hereby appoint the practitioners associated with the Customer Number. 49680								
Please change the correspondence address for the above-identified application to: The address associated with								
Customer Nu		49580	·					
Firm or Individual Name	Philip A. Swain	clo Gowling	, Lafleur Henderson U.F					
Address	1 Place VilleMarie 37th Floor							
City	montreal	State Quebec	Zip H3B 3P4 c					
Country	Canada							
Telephone	514-392-9562	Email phil	10. Swain @ goullings ic					
l am the: Applicant/Inventor.								
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)								
Cinata Park	SIGNATURE of Applican	t or Assignee of Rec	ord					
Signature - Lec'III								
Name D, Joe Irvine								
Date 7A	n 2006		-562-5800 #5800					
NOTE: Signatures of all the infentors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.								
'Total of 1forms are submitted.								

This collection of information is required by 37 CFR 1.38. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1,14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRCSS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER MAY 1 9 2006

Docket No; 110-C1

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Applicants:	Robert G. Korneluk, Eric LaCasse, Stephen Baird, Martin Sean Young.	Holcik,						
Application	No: 10/636,065 Filed: August 7, 2003							
For:	Antisense IAP Oligonucleotides and Uses Thereof	Antisense IAP Oligonucleotides and Uses Thereof						
	University of Ottawa,							
States that it is								
A. 🖾	the assignee of the entire right, title and interest in the patent application identified above; or							
в. 🗆	the assignee together with { } of the entire right, title and interest in the patent application identified above.							
The right, title and interest of the above-named assignee in the patent application identified above are established by virtue of;								
A. 🗵	An assignment from the inventor(s) of the patent application identified above.							
в. 🗀	A chain of title from the inventor(s) of the patent application identabove, to the current assignee as shown below:	tified						
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.								
Date:	Apr. 4 2006							
Name:	Joe Irvine							
Title:	ctor of Technology Transfer University of Ottawa							
Signature:	De Jeine							